Matches in Nanopublications for { ?s ?p "[Activating mutations in the phosphoinositide-3-kinase (PI3K)/AKT/mTOR pathway are present in the majority of breast cancers and therefore are a major focus of drug development and clinical trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 11 of
11
with 100 items per page.
- NP623519.RAbyZ57HP0iWa-9ocH4Me9EjDJ8D0fnmr0MsH1FByVAmo130_assertion description "[Activating mutations in the phosphoinositide-3-kinase (PI3K)/AKT/mTOR pathway are present in the majority of breast cancers and therefore are a major focus of drug development and clinical trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP623519.RAbyZ57HP0iWa-9ocH4Me9EjDJ8D0fnmr0MsH1FByVAmo130_provenance.
- assertion description "[Activating mutations in the phosphoinositide-3-kinase (PI3K)/AKT/mTOR pathway are present in the majority of breast cancers and therefore are a major focus of drug development and clinical trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Activating mutations in the phosphoinositide-3-kinase (PI3K)/AKT/mTOR pathway are present in the majority of breast cancers and therefore are a major focus of drug development and clinical trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Activating mutations in the phosphoinositide-3-kinase (PI3K)/AKT/mTOR pathway are present in the majority of breast cancers and therefore are a major focus of drug development and clinical trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1097013.RAR2qDH-otRKaGHlkH3Oa4LRsIltthg9nmKJmVUSw2TC0130_assertion description "[Activating mutations in the phosphoinositide-3-kinase (PI3K)/AKT/mTOR pathway are present in the majority of breast cancers and therefore are a major focus of drug development and clinical trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1097013.RAR2qDH-otRKaGHlkH3Oa4LRsIltthg9nmKJmVUSw2TC0130_provenance.
- NP622204.RAiq3umdnsmHl4ZPGbbAS9tGviBlDWCNOY016LJlGP_YI130_assertion description "[Activating mutations in the phosphoinositide-3-kinase (PI3K)/AKT/mTOR pathway are present in the majority of breast cancers and therefore are a major focus of drug development and clinical trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP622204.RAiq3umdnsmHl4ZPGbbAS9tGviBlDWCNOY016LJlGP_YI130_provenance.
- NP624647.RAEu6JpT7EaGZDAjasxyAg6D4zOoygi87n-clzsKMwepk130_assertion description "[Activating mutations in the phosphoinositide-3-kinase (PI3K)/AKT/mTOR pathway are present in the majority of breast cancers and therefore are a major focus of drug development and clinical trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP624647.RAEu6JpT7EaGZDAjasxyAg6D4zOoygi87n-clzsKMwepk130_provenance.
- NP620750.RA9ZVX1bb_JNotbXikhuVdzzoIOTZk3jFgRxIliHwWggI130_assertion description "[Activating mutations in the phosphoinositide-3-kinase (PI3K)/AKT/mTOR pathway are present in the majority of breast cancers and therefore are a major focus of drug development and clinical trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP620750.RA9ZVX1bb_JNotbXikhuVdzzoIOTZk3jFgRxIliHwWggI130_provenance.
- NP1097011.RAO6W-sj9eJ4-5b-VNP3JJwxE6HZkb2xDxPjZvKQEl2vY130_assertion description "[Activating mutations in the phosphoinositide-3-kinase (PI3K)/AKT/mTOR pathway are present in the majority of breast cancers and therefore are a major focus of drug development and clinical trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1097011.RAO6W-sj9eJ4-5b-VNP3JJwxE6HZkb2xDxPjZvKQEl2vY130_provenance.
- NP1097010.RA7INDT9-JdRRmqVmUxoTtTMOSi1S4i85hNmn3F0cf8wY130_assertion description "[Activating mutations in the phosphoinositide-3-kinase (PI3K)/AKT/mTOR pathway are present in the majority of breast cancers and therefore are a major focus of drug development and clinical trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1097010.RA7INDT9-JdRRmqVmUxoTtTMOSi1S4i85hNmn3F0cf8wY130_provenance.
- NP1097015.RA9aPgsG27tmu8MLyX3B-SHCiHDeARfTT02iUbtL8ibk4130_assertion description "[Activating mutations in the phosphoinositide-3-kinase (PI3K)/AKT/mTOR pathway are present in the majority of breast cancers and therefore are a major focus of drug development and clinical trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1097015.RA9aPgsG27tmu8MLyX3B-SHCiHDeARfTT02iUbtL8ibk4130_provenance.